­

June 2016

New publication in the prestige “Journal of Arthroplasty” demonstrates that Using an IPCD and TXA and discontinuing enoxaparin and preoperative autologous blood donation eliminated blood transfusion in primary THA and [...]

June 2016

Activecare® gets additional evidence for its efficiency: New publication in the prestige “Journal of Arthroplasty” Confirming Patient Satisfaction, Safety, Efficacy and Reduction of Hospital Readmissions with ActiveCare® DVT prophylaxis Mobile [...]

  • Graph

1- “Use of the mobile compression device with or without aspirin for patients undergoing arthroplasty of a lower-extremity joint provides a no inferior risk for the development of venous thromboembolism compared with current pharmacological protocols.”

A Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty C. Colwell, M. Froimson, M. Mont, M. Ritter, R. Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett. The Journal [...]

2- “Our analysis shows that mobile, synchronized mechanical compression after major orthopedic surgery of the lower extremity is associated with significant cost savings of $369.5 per patient.”

Cost-Effectiveness of Venous Thromboembolism Prophylaxis With a New Mobile Device After Total Hip Arthroplasty C. Colwell, M. Froimson, M. Mont, M. Ritter, R.Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett. [...]

3- “When compared with low-molecular-weight heparin, use of the mobile compression device for prophylaxis against venous thromboembolic events following total hip arthroplasty resulted in a significant decrease in major bleeding events.”

Thrombosis Prevention after Total Hip Arthroplasty. C. Colwell, M. Froimson, M. Mont, M. Ritter, R.Trousdale, K. Buehler, A. Spitzer, T. Donaldson, D. Padgett. The Journal of Bone and Joint Surgery, March [...]

4- “…We found a significantly lower prevalence of deep vein thrombosis with this combination than with the standard enoxaparin prophylaxis. This combined prophylaxis protocol has favorable risk-benefit and cost effectiveness profiles…”

DVT Prevention in Joint Arthroplasties: Continuous Enhanced Circulation Therapy vs. Low Molecular Weight Heparin. Y. Gelfer, H. Tavor, A. Or on, A. Peer, N. Halperin, D. Robinson. The Journal of [...]

5- “…We found the evidence from this study convincing and the technological features of this novel device sufficient to support the selection of the CECT device for exclusive use at our institution. The CECT device used over our routine chemical agents significantly reduced the VTE events compared to the previous regimen of a fixed IPC device used with the same chemical agents…”

Venous Thromboembolic Disease Reduction with a Portable Pneumatic Compression Device. M. Froimson, T. Murray, A. Fazekas Journal of Arthroplasty February 2009; 24(2): 310-316 : Read more ActiveCare® + Enxoparin is [...]

6- “…significant reduction in rate of DVT after TKA when the CECT device was combined with LMWH…”

Portable Compression Device and LMWH Compared with LMWH for Thromboprophylaxis after Total Joint Arthroplasty. J. Edwards, P. Pulido, K. Ezzet, S. Copp, R. Walker,  C. Colwell Journal of Arthroplasty, December 2008; [...]

More clinical studies:

Compliance in Trauma Patients
M. Murakami, T. McDill, L. Cindrick-Pounds, D. Loran, K. Woodside, W. Mileski,
G. Hunter and L. Killewich
Deep Venous Thrombosis Pophylaxis in Trauma: Improved Compliance With a Novel Miniaturized Pneumatic Compression Device
Journal of Vascular Surgery, November 2003; 38(5): 923-927

Compliance in Gynecologic Patients 
M. Kahan, C. Lord, M. Murakami, J. Lucci, L. Killewich
Deep Venous Thrombosis Prophylaxis in Gynecologic Surgery:
Improved Compliance With a Novel Miniaturized Pneumatic  Compression Device
Journal of Pelvic Medicine and Surgery, 2003; 9 (sup 1)

ActiveCare®+Enoxaparin vs Enoxaparin
G. Rosenthal, F. Umansky, S. Goldman, G. Spector, D. Varone, Y. Weiss, M. Brazis
How to Prevent Venous Thromboembolism After Brain Surgery?
Quality Saves Costs.
Hadassah Medical Center – Ein Karem, Israel

Fill in this form and we'll get back to you

Your title:

First Name:
Last Name:
Phone:
Email:


lower
the
risk.

cut
the
cost.